These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Intracellular distribution of norepinephrine in rat brain. I. Effect of reserpine and the monoamine oxidase inhibitors, trans-2-phenylcyclopropylamine and 1-isonicotinyl-2-isopropyl hydrazine. GREEN H, SAWYER JL. J Pharmacol Exp Ther; 1960 Jul; 129():243-9. PubMed ID: 13851489 [No Abstract] [Full Text] [Related]
3. [Action on behavior of the combination of tranylcypromine and reserpine]. BABBINI M, RICCIONI ML, MISSERE G, TONINI G. Arch Ital Sci Farmacol; 1961 Oct; 11():310-2. PubMed ID: 13863628 [No Abstract] [Full Text] [Related]
8. Effect of trans-2-phenylcycloproplylamine upon norepinephrine concentration and monamine oxidase activity of rat brain. GREEN H, ERICKSON RW. J Pharmacol Exp Ther; 1960 Jul; 129():237-42. PubMed ID: 13851486 [No Abstract] [Full Text] [Related]
9. Tranylcypromine (parnate) a new monoamine oxidase inhibitor. LEMERE F. Am J Psychiatry; 1960 Sep; 117():249. PubMed ID: 14415582 [No Abstract] [Full Text] [Related]
10. [Effect of dihydroxyphenylalanine on the serotonin content of rat brain following pretreatment with monoamine oxidase inhibitors]. Popov N, Matthies H. Acta Biol Med Ger; 1966 Sep; 17(5):637-43. PubMed ID: 5991588 [No Abstract] [Full Text] [Related]
11. Action of reserpine and monoamine oxidase inhibitors on the urinary excretion of catecholamines in the rat. BICKEL MH, CARPI A, BOVET D. Helv Physiol Pharmacol Acta; 1961 Sep; 19():279-84. PubMed ID: 13868969 [No Abstract] [Full Text] [Related]
12. The effect of reserpine and monoamine oxidase inhibitors on paradoxical sleep in the monkey. Reite M, Pegram GV, Stephens LM, Bixler EC, Lewis OL. Psychopharmacologia; 1969 Sep; 14(1):12-7. PubMed ID: 4310917 [No Abstract] [Full Text] [Related]
13. Some pharmacological observations on tranylcypromine (SKF trans-385), a potent inhibitor of monoamine oxidase. TEDESCHI RE, TEDESCHI DH, AMES PL, COOK L, MATTIS PA, FELLOWS EJ. Proc Soc Exp Biol Med; 1959 Nov; 102():380-1. PubMed ID: 13837261 [No Abstract] [Full Text] [Related]
16. Tranylcypromine and the extrapyramidal syndromes. BARBEAU A, DUCHASTEL Y. Can Psychiatr Assoc J; 1962 Nov; 7(Suppl)():91-5. PubMed ID: 13864822 [No Abstract] [Full Text] [Related]
17. The relative merits of tranylcypromine alone and tranylcypromine in combination with trifluoperazine in the treatment of patients with severe agitated depressions. LESSE S. Am J Psychiatry; 1962 Apr; 118():934-5. PubMed ID: 14464348 [No Abstract] [Full Text] [Related]
18. Cardiovascular effects of (+)- and (-)-tranylcypromine compared to other monoamine oxidase inhibitors. Greeff K, Dènes B, Tawfik H. Mod Probl Pharmacopsychiatry; 1983 Apr; 19():220-30. PubMed ID: 6408408 [No Abstract] [Full Text] [Related]
19. The effect of tranylcypromine-trifluoperazine in the treatment of depressive states. BRAM G. Can Psychiatr Assoc J; 1962 Apr; 7(Suppl)():84-6. PubMed ID: 13872435 [No Abstract] [Full Text] [Related]
20. MECHANISM OF ACTION OF MONOAMINE OXIDASE INHIBITORS IN ENHANCING AMPHETAMINE TOXICITY. BRITTAIN RT, JACK D, SPENCER PS. J Pharm Pharmacol; 1964 Aug; 16():565-7. PubMed ID: 14223999 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]